Bris­tol-My­ers shares sink af­ter an­oth­er set­back for its im­muno-on­col­o­gy fran­chise drugs

Once again un­der­min­ing con­fi­dence in its all-im­por­tant im­muno-on­col­o­gy pipeline, Bris­tol-My­ers Squibb con­ced­ed Tues­day evening that a com­bi­na­tion of Op­di­vo and Yer­voy failed to hit a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER